Angiogenic inhibitors: a new therapeutic strategy in oncology

摘要: Based on preclinical data, it has been suggested that antiangiogenic compounds could improve cytotoxic drug delivery because of their effects tumor endothelium. Most the early clinical testing these agents was conducted in patients with advanced disease resistant to standard therapies, and while some phase III trial data were disappointing, recent studies validated large trials anti-VEGF antibody, bevacizumab, demonstrated significant benefit renewed enthusiasm for this therapeutic strategy. This review highlights challenges related choosing appropriate strategies selection patients, study design, choice endpoints development agents. Angiogenesis is a multistep, complex tightly regulated process necessary growth metastasis. models, several shown modify activated endothelium, which suggests can delivery. Such have entered as single or combination drugs, promising antitumor activity. The pharmacodynamic pharmacokinetic characteristics drugs are reviewed here. therapies. Phase compared efficacy chemotherapy alone an experimental angiogenesis inhibitor. Although negative controversial, anti-vascular endothelial factor antibody describes design studies' development.